TP53 and cancer: Importantly, mouse models and clinical data from germline and sporadic cancers have now firmly established that p53 missense mutations not only abolish the tumor suppressive function, but also often acquire new tumorigenic driver activities (gain-of-function, GOF) [2,3,4,5].